- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Top 5 AJMC® Stories of the Week: March 2, 2020
The most popular stories of the week on AJMC®.
FDA Steps Up Warning for Montelukast for Risk of Mental Health Side Effects
The FDA now requires a boxed warning for montelukast (Singulair) due to the risk of neuropsychiatric events associated with the drug.
Study Finds Tai Chi Exercises May Prove Effective for Patients With Parkinson Disease
In individuals with mild to moderate Parkinson disease, Tai Chi was shown to be a potentially effective meditation technique that may slow down disease progression, according to study findings.
JAMA: List Prices for Key Drugs More Than Doubled Over 10-Year Period
A special issue takes a wide-ranging look at the cost of prescription drugs.
Learning From the Oncology Care Model to Move APMs Forward
Implementing alternative payment models in oncology is a complicated process. The models are not perfect, especially the Centers for Medicare and Medicaid Services’ Oncology Care Model (OCM), although several panelists saw improvements in the proposed successor model, Oncology Care First (OCF).
Variation in Systolic BP Appears to Correlate With Multiple Sclerosis Disability
A new study suggests patients whose systolic blood pressure varies significantly over time might be at greater risk of higher multiple sclerosis disability.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
